research use only
Cat.No.S1636
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV |
|---|---|
| Other Antibiotics for Mammalian Cell Culture Inhibitors | Tylosin tartrate |
|
In vitro |
DMSO
: 4.5 mg/mL
(4.86 mM)
Water : 4.5 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 924.08 | Formula | C47H73NO17 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1397-89-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC 527017 | SMILES | CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
ergosterol
|
|---|---|
| In vitro |
Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. This compound induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. It interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of this chemical due to its relatively high toxicity. This drug is dispersed as a pre-micellar or as a highly aggregated state in the subphase. It only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. This compound (0.1 mM) induces a polarization potential, indicating K+ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. It (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na+ entry into the cells.
|
| In vivo |
Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. This compound markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE). It exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia and hostsurvival in murine malaria. This chemical tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-07-27)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05814432 | RECRUITING | Disseminated Histoplasma Capsulatum Infection; AIDS and Infections; Immunosuppression; Fungal Infection |
Federal University of Health Science of Porto Alegre |
2025-01-16 | PHASE3 |
| NCT06525389 | NOT_YET_RECRUITING | Talaromycosis |
Duke University |
2026-09-01 | PHASE3 |
| NCT07463040 | NOT_YET_RECRUITING | Cutaneous Leihmaniasis |
Institute of Tropical Medicine, Belgium |
2027-01-01 | PHASE3 |
| NCT07559032 | NOT_YET_RECRUITING | Invasive Fungal Disease |
Peking University People's Hospital |
2026-04 | |
| NCT07725874 | NOT_YET_RECRUITING | Invasive Mold Diseases |
Beijing Friendship Hospital |
2026-08-08 | |
| NCT07530263 | NOT_YET_RECRUITING | Chronic Pulmonary Aspergillosis |
Radboud University Medical Center |
2026-10-01 | PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.